Identity
Other names: MRP (multidrug resistanceassociated protein) HGNC (Hugo): ABCC1 Location: 16p13.1 Note: MRP is a gene involved in multidrug resistance, discovered in a multidrug-resistant, Pglycoprotein negative, non small cell lung carcinoma cell line. 
DNA/RNA

Expression
Expressed at a basal level in a wide variety of normal tissues, including epithelial cells and all hematopoietic cell types, which suggests a function common to most cell types; increased expression in various tumor cell type.
Localisation
In normal cells, predominant localisation in the cytoplasm; in tumor cells, predominant in plasma membrane, but also found in endoplasmic reticulum, indicating a probable different function as in normal cells.
Function
Plasma membrane drug-efflux pump; MRP induces a multidrug resistance phenotype (MDR phenotype); overexpression confers tumor cell resistance to a wide variety of hydrophobic drugs: doxorubicin, daunorubicin, vinblastine, vincristine, colchicine, VP16, Rhodamin 123; glutathione is required for the effective expulsion of the chemotherapeutic agents; the mode of action of MRP is very similar to the one of P-glycoprotein, the main protein responsible for the MDR phenotype; however, MRP does not confer resistance to Taxol or m-AMSA, but it is able to transport metallic oxyanions, glutathione and other glutathione conjugates; inhibitors of organic anion transport, such as probenecid, can block MRP activity.
Homology
Structural and/or functional homology with other ABC transporter proteins (CFTR, Pgp, MOAT).
Implicated in
Induced resistance to chemotherapeutic agents
ABCC1 (ATP-binding cassette, sub-family C (CFTR/MRP), member 1) Viguié F Atlas Genet Cytogenet Oncol Haematol. 1999; 3(1)
Disease
In a wide variety of solid and hematological tumors. Oncogenesis MRP hyperexpression may confer therapeutic resistance in leukemia and solid tumor; however its relative importance, in comparison with other proteins able to induce the MDR phenotype (P-gp, LRP), is not yet clear; hyperexpression is probably linked to transcriptional activation of the gene and/or increased mRNA stability, and not to gene amplification; increased expression of MRP mRNA and protein is a factor of bad prognostic in neuroblastoma, retinoblastoma, and non small cell lung carcinoma. In haematological malignancies, overexpression is frequent in chronic lymphocytic leukemia and prolymphocytic leukemia, occasional in acute myeloid leukemia and rare in acute lymphoid leukemia, lymphoma, multiple myeloma and myeloproliferative disorders.
